Molecular methods to detect the Philadelphia chromosome

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• The Philadelphia chromosome (Ph1) is a hallmark of certain leukemias, including Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL).
• Ph1 chromosome exhibits two molecular subtypes: bcr-positive and bcr-negative, with distinct associations with CML and ALL.
• Traditional cytogenetic methods have limitations in detecting Ph1 chromosome, especially in ALL where breakpoints are scattered.

Purpose of the Study:

• To evaluate molecular methods for detecting the Ph1 chromosome and its subtypes in CML and ALL.
• To compare the efficacy of molecular techniques versus cytogenetics for identifying chromosomal abnormalities.
• To assess the utility of sensitive molecular methods for detecting minimal residual disease (MRD) post-treatment.

Main Methods:

• Southern blot analysis for detecting bcr rearrangements in CML.
• Pulsed-field gel electrophoresis (PFGE) and Polymerase Chain Reaction (PCR) for detecting Ph1 chromosome in ALL.
• Modified PCR using complementary DNA (cDNA) from messenger RNA (mRNA) for sensitive detection and subtyping.

Main Results:

• Molecular methods, including PCR, are crucial for detecting the Ph1 chromosome in ALL due to scattered translocation breakpoints.
• Molecular detection of Ph1 chromosome and its subtypes can be superior to cytogenetics in both CML and ALL.
• Modified PCR demonstrates exquisite sensitivity for detecting minimal residual disease (MRD) in CML and ALL, even after intensive therapies like bone marrow transplantation.

Conclusions:

• Molecular techniques offer a more sensitive and comprehensive approach to diagnosing and monitoring Ph1-positive leukemias.
• PCR is particularly valuable for detecting minimal residual disease, aiding in post-treatment surveillance.
• The prognostic significance of low-level fusion gene expression detected by sensitive methods requires further investigation.